It is over 60 years since Lp(a) was identified as a new serum type antigen associated with lipoproteins, but more recent advances in understanding of the structure and function of Lp(a) have led to the recognition of its importance as a cardiovascular risk factor, as Lp(a) Forum Co-Chair, Professor Henry Ginsberg explains.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.